Recursion Pharmaceuticals Inc (NASDAQ:RXRX) price on Thursday, June 12, fall -4.26% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $5.17.
A look at the stock’s price movement, the close in the last trading session was $5.40. Turning to its 52-week performance, $12.36 and $3.79 were the 52-week high and 52-week low respectively. Overall, RXRX moved 14.63% over the past month.
Recursion Pharmaceuticals Inc’s market cap currently stands at around $2.10 billion, with investors looking forward to this quarter’s earnings report slated for in July.
Analysts have a consensus estimate of 16.23M for the company’s revenue for the quarter, with a low and high estimate of 5M and 27.7M respectively. The average forecast suggests up to a 12.60% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 74.25M, representing a 26.18% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RXRX is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend RXRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RXRX’s current price about 11.51% and 6.01% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 55.10, while 7-day volatility ratio is 2.44% and 6.51% in the 30-day chart. Further, Recursion Pharmaceuticals Inc (RXRX) has a beta value of 0.86, and an average true range (ATR) of 0.45. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -16.05% off current price level while to achieve the yearly target high, price needs to move -16.05%. Nonetheless, investors will most likely welcome a -16.05% jump to $6 which is the analysts’ median price.
If we refocus on Recursion Pharmaceuticals Inc (NASDAQ:RXRX), historical trading data shows that trading volumes averaged 22.49 million over the past 3 months. The company’s latest data on shares outstanding shows there are 399.15 million shares.
The 23.55% of Recursion Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 60.52% of the company’s shares. Current price change has pushed the stock -23.52% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RXRX stock continues to rise going into the next quarter.
